{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:00:54Z","timestamp":1768568454162,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Vitiligo is a cutaneous disease caused by the destruction of functioning melanocytes. Cellular immunity is known to have a role in the pathogenesis of vitiligo. Macrophage migration inhibitory factor (MIF) is a potent activator of macrophages and is considered to play an important role in cell-mediated immunity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>We tried to investigate the association between MIF (rs755622) gene polymorphism and vitiligo susceptibility and its relationship to severity and clinical types of the disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fifty patients with vitiligo and 50 healthy controls were included. Determination of MIF gene (rs755622) single nucleotide polymorphism was conducted using polymerase chain reaction (PCR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 18 males and 32 females who had vitiligo, together with 50 control participants of matched age and gender. Taking GG genotype and G allele as references, MIF GC, CC, (GC\u2009+\u2009CC) genotypes, and C allele demonstrated a substantially higher occurrence in all patients when compared to controls, with a higher risk of developing vitiligo within healthy control subjects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>To the best of our knowledge, this is the third study worldwide and the first from Egypt to investigate the association between MIF gene polymorphism (rs755622) with vitiligo susceptibility and severity, and it showed that MIF gene polymorphism (rs755622) may be considered a risk factor for vitiligo susceptibility. Moreover, it may be associated with higher disease extent.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11845-025-03966-9","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:38:07Z","timestamp":1748565487000},"page":"933-938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Macrophage migration inhibitory factor (rs755622) gene polymorphism in vitiligo"],"prefix":"10.1007","volume":"194","author":[{"given":"Doaa Falih","family":"Hadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel-Aziz Ibrahim","family":"El-Taweel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amany Ibrahim","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola Samir","family":"El-Shimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-9748","authenticated-orcid":false,"given":"Mahmoud A.","family":"Rageh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"6","key":"3966_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K (2020) Vitiligo: a review. Dermatology 236(6):571\u2013592","journal-title":"Dermatology"},{"issue":"7","key":"3966_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1468-3083.2007.02228.x","volume":"21","author":"N Rezaei","year":"2007","unstructured":"Rezaei N, Gavalas NG, Weetman AP, Kemp EH (2007) Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 21(7):865\u2013876","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9988","key":"3966_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo Lancet 386(9988):74\u201384","journal-title":"Vitiligo Lancet"},{"issue":"5 Suppl 2","key":"3966_CR4","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/j.jaad.2005.12.042","volume":"54","author":"P Grimes","year":"2006","unstructured":"Grimes P, Nordlund JJ, Pandya AG et al (2006) Increasing our understanding of pigmentary disorders. J Am Acad Dermatol 54(5 Suppl 2):S255\u2013S261","journal-title":"J Am Acad Dermatol"},{"key":"3966_CR5","doi-asserted-by":"crossref","unstructured":"Budarf M, McDonald T, Sellinger B, Kozak C, Graham C, Wistow G (1997) Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. Genomics 39(2):235\u20136","DOI":"10.1006\/geno.1996.4505"},{"issue":"20","key":"3966_CR6","doi-asserted-by":"publisher","first-page":"8224","DOI":"10.1073\/pnas.1017624108","volume":"108","author":"Y Al-Abed","year":"2011","unstructured":"Al-Abed Y, Metz CN, Cheng KF and others (2011) Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. Proc Natl Acad Sci U S A 108(20):8224\u20138227","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3966_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jdermsci.2004.08.007","volume":"37","author":"T Shimizu","year":"2005","unstructured":"Shimizu T (2005) Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 37(2):65\u201373","journal-title":"J Dermatol Sci"},{"issue":"5","key":"3966_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.62.5.460","volume":"62","author":"E Selvi","year":"2003","unstructured":"Selvi E, Tripodi SA, Catenaccio M and others (2003) Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis 62(5):460\u2013464","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3966_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2567.2008.02879.x","volume":"126","author":"I Stojanovi\u0107","year":"2009","unstructured":"Stojanovi\u0107 I, Cvjeti\u0107anin T, Lazaroski S et al (2009) Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 126(1):74\u201383","journal-title":"Immunology"},{"key":"3966_CR10","doi-asserted-by":"publisher","first-page":"750342","DOI":"10.1155\/2011\/750342","volume":"2011","author":"T Kawakami","year":"2011","unstructured":"Kawakami T, Hashimoto T (2011) Disease severity indexes and treatment evaluation criteria in vitiligo. Dermatol Res Pract 2011:750342","journal-title":"Dermatol Res Pract"},{"issue":"10","key":"3966_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1468-3083.2007.02283.x","volume":"21","author":"A Bhatnagar","year":"2007","unstructured":"Bhatnagar A, Kanwar AJ, Parsad D, De D (2007) Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study. J Eur Acad Dermatol Venereol 21(10):1381\u20131385","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3966_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1042\/CS20090603","volume":"120","author":"SJ Glassman","year":"2011","unstructured":"Glassman SJ (2011) Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond) 120(3):99\u2013120","journal-title":"Clin Sci (Lond)"},{"key":"3966_CR13","doi-asserted-by":"publisher","first-page":"8065765","DOI":"10.1155\/2016\/8065765","volume":"2016","author":"L Lazzeri","year":"2016","unstructured":"Lazzeri L, Colucci R, Cammi A et al (2016) Adult onset vitiligo: multivariate analysis suggests the need for a thyroid screening. Biomed Res Int 2016:8065765","journal-title":"Biomed Res Int"},{"key":"3966_CR14","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3389\/fimmu.2018.02262","volume":"9","author":"S Bezdek","year":"2018","unstructured":"Bezdek S, Leng L, Busch H and others (2018) Macrophage migration inhibitory factor (MIF) drives murine psoriasiform dermatitis. Front Immunol 9:2262","journal-title":"Front Immunol"},{"key":"3966_CR15","first-page":"1219","volume":"148","author":"IC Le Poole","year":"1996","unstructured":"Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK (1996) Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 148:1219\u20131228","journal-title":"Am J Pathol"},{"key":"3966_CR16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","volume":"80","author":"R van den Wijngaard","year":"2000","unstructured":"van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C et al (2000) Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 80:1299\u20131309","journal-title":"Lab Invest"},{"issue":"5","key":"3966_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1590\/S0100-879X2012007500152","volume":"46","author":"L Ma","year":"2013","unstructured":"Ma L, Xue HB, Guan XH et al (2013) Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and activity in vitiligo vulgaris. Braz J Med Biol Res 46(5):460\u2013464","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"3966_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2230.2009.03617.x","volume":"35","author":"G Serarslan","year":"2010","unstructured":"Serarslan G, Y\u00f6nden Z, S\u00f6\u011f\u00fct S et al (2010) Macrophage migration inhibitory factor in patients with vitiligo and relationship between duration and clinical type of disease. Clin Exp Dermatol 35(5):487\u2013490","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"3966_CR19","first-page":"8265","volume":"11","author":"MI ElGhareeb","year":"2019","unstructured":"ElGhareeb MI, Mokadem SE, Sayed BE, Khalifa N (2019) Soluble CD27 and MIF as possible serum biomarkers of vitiligo activity in Egyptian patients in Sharkia Governorate. Dermatol Reports 11(2):8265","journal-title":"Dermatol Reports"},{"issue":"10","key":"3966_CR20","first-page":"24","volume":"13","author":"F Eldesouky","year":"2020","unstructured":"Eldesouky F, Ibrahim AM, Sharaf SM (2020) Macrophage migration inhibitory factor in alopecia areata and vitiligo: a case-controlled serological study. J Clin Aesthet Dermatol 13(10):24\u201327","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"3966_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1590\/abd1806-4841.20186068","volume":"93","author":"AGA Farag","year":"2018","unstructured":"Farag AGA, Hammam MA, Habib MS et al (2018) Macrophage migration inhibitory factor as an incriminating agent in vitiligo. An Bras Dermatol 93(2):191\u2013196","journal-title":"An Bras Dermatol"},{"key":"3966_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2147\/CCID.S369418","volume":"15","author":"D Wang","year":"2022","unstructured":"Wang D, Min S, Lin X, Jiang G (2022) Association among MIF, IFIH1, and IL6 gene polymorphisms and non-segmental vitiligo in a Chinese Han population. Clin Cosmet Investig Dermatol 15:1597\u20131609","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"3966_CR23","doi-asserted-by":"publisher","first-page":"e1416","DOI":"10.1002\/mgg3.1416","volume":"8","author":"A Garcia-Orozco","year":"2020","unstructured":"Garcia-Orozco A, Martinez-Maga\u00f1a IA, Riera-Leal A et al (2020) Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico. Mol Genet Genomic Med 8(10):e1416","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"3966_CR24","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1111\/j.1365-4632.2012.05597.x","volume":"53","author":"L Ma","year":"2014","unstructured":"Ma L, Xue HB, Guan XH et al (2014) Macrophage migration inhibitory factor promoter 173G\/C polymorphism is associated with atopic dermatitis risk. Int J Dermatol 53(1):e75\u2013e77","journal-title":"Int J Dermatol"},{"issue":"3","key":"3966_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000489340","volume":"27","author":"AF Nursal","year":"2018","unstructured":"Nursal AF, Yigit S, Tural E et al (2018) Macrophage migration inhibitory factor -173GC variant might increase the risk of Beh\u00e7et\u2019s disease. Med Princ Pract 27(3):285\u2013289","journal-title":"Med Princ Pract"},{"issue":"3","key":"3966_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00418-002-0435-x","volume":"118","author":"T Shimizu","year":"2002","unstructured":"Shimizu T, Nishihira J, Mizue Y et al (2002) Histochemical analysis of macrophage migration inhibitory factor in psoriasis vulgaris. Histochem Cell Biol 118(3):251\u2013257","journal-title":"Histochem Cell Biol"},{"issue":"4","key":"3966_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/sj.gene.6364191","volume":"6","author":"T Shimizu","year":"2005","unstructured":"Shimizu T, Hizawa N, Honda A et al (2005) Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun 6(4):285\u2013289","journal-title":"Genes Immun"},{"issue":"2","key":"3966_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-4632.2009.04238.x","volume":"49","author":"MR Namazi","year":"2010","unstructured":"Namazi MR, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E (2010) Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol 49(2):146\u2013148","journal-title":"Int J Dermatol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03966-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:17:53Z","timestamp":1757175473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03966-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3966"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03966-9","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Benha University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was obtained from all participants after being informed about the nature of the study, including consent for participation and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}